Global Intravitreal Injection Market Growth 2024-2030

Global Intravitreal Injection Market Growth 2024-2030

Intravitreal injection is a drug that is injected directly into the vitreous cavity of the eye and is mainly used to treat various fundus diseases.

The global Intravitreal Injection market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Intravitreal Injection Industry Forecast” looks at past sales and reviews total world Intravitreal Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Intravitreal Injection sales for 2024 through 2030. With Intravitreal Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injection industry.

This Insight Report provides a comprehensive analysis of the global Intravitreal Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intravitreal Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injection.

United States market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Intravitreal Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Intravitreal Injection players cover Sanofi, Novartis, Bayer, Genentech and Apellis Pharmaceuticals, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Ranibizumab
Bevacizumab
Aflibercept
Brolucizumab
Faricimab
Others

Segmentation by application
Diabetic Eye Disease
AMD
Retinal Vein Occlusion
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
Bayer
Genentech
Apellis Pharmaceuticals, Inc.
Coherus BioSciences Inc.
Iveric Bio
Regeneron
Roche
Qilu Pharmaceutical Co.,Ltd.
Chengdu Kanghong Pharmaceutical Group

Key Questions Addressed in this Report

What is the 10-year outlook for the global Intravitreal Injection market?

What factors are driving Intravitreal Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Intravitreal Injection market opportunities vary by end market size?

How does Intravitreal Injection break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.